-
Mashup Score: 4
Over the last 20 years, standard-of-care therapies for metastatic renal cell carcinoma (mRCC) have progressed from cytokines and vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs) to immune checkpoint inhibition (ICI)–based treatment. The availability of these , however, can vary worldwide.
Source: www.medpagetoday.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Chromophobe Renal Cell Carcinoma - Beyond the Abstract - 19 day(s) ago
renal cell carcinomas (vhRCCs), clear cell renal cell carcinoma (ccRCC), renal cell carcinoma (RCC), kidney cancer, vacuolar ATPase (v-ATPase), Tuberous Sclerosis Complex (TSC), mechanistic target of rapamycin complex 1 (mTORC1), innate lymphoid cells type 1 (ILC1s), mTOR pathways, PTEN mutations, Birt-Hogg-Dube syndrome (BHD).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Delve into the intricate world of Chromophobe #RCC with our latest review! Discover the unique pathogenic mechanisms, potential therapeutic targets, and challenges in advancing research and treatment with Elizabeth Henske and Melissa Daou @BrighamWomens > https://t.co/AevweMyNAH https://t.co/Q3Fi9n6al1
-
-
Mashup Score: 0Advances in Therapeutic Strategies for Advanced Renal Cell Carcinoma: A Comprehensive Review - 19 day(s) ago
Advanced renal cell carcinoma (RCC), advanced RCC management, Adjuvant Therapies for ccRCC, HIF-2α inhibitor belzutifan, First-line treatment of advanced unresectable ccRCC, FDA approval for treating advanced RCC.
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Advances in therapeutic strategies for advanced #RCC: a comprehensive review. @PBarataMD discusses current therapeutic approaches for pts with advanced RCC, including clear cell and other histotypes and the role of (neo)adjuvant treatment and biomarkers > https://t.co/nTEpK3ly7m https://t.co/Qg71JYSk6H
-
-
Mashup Score: 1
During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Next Steps in Study of PPAR-α Inhibitor Plus Nivolumab in RCC - 25 day(s) ago
Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 163Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma - 26 day(s) ago
AbstractThe phase III JAVELIN Renal 101 trial demonstrated prolonged progression-free survival (PFS) in patients (N = 886) with advanced renal cell carcinoma treated with first-line avelumab + axitinib (A+Ax) versus sunitinib. We report novel findings from integrated analyses of longitudinal blood samples and baseline tumor tissue. PFS was associated with elevated lymphocyte levels in the sunitinib arm and an abundance of innate immune subsets in the A+Ax arm. Treatment with A+Ax led to greater T-cell repertoire modulation and less change in T-cell numbers versus sunitinib. In the A+Ax arm, patients with tumors harboring mutations in ≥2 of 10 previously identified PFS-associated genes (double mutants) had distinct circulating and tumor-infiltrating immunologic profiles versus those with wild-type or single-mutant tumors, suggesting a role for non–T-cell–mediated and non–natural killer cell–mediated mechanisms in double-mutant tumors. We provide evidence for different immunomodulatory m
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Study Links Prior Thymectomy to Higher Rate of Nephrectomy in RCC - 1 month(s) ago
Regina Barragan-Carrillo, MD, discusses findings from a large population-based study which found there to be significantly higher rates of nephrectomy among patients with renal cell carcinoma who had received prior thymectomy vs the incidence of nephrectomy overall.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9PPAR-α Inhibitor Plus Nivolumab Shows Promise in RCC - 2 month(s) ago
Bruno R. Bastos, MD, discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with renal cell carcinoma who were treated with the combination of nivolumab and TPST-1120.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Kidney cancer is the seventh leading cause of cancer in the world, and its incidence is on the rise. Renal cell carcinoma (RCC) is the most common form and is a heterogeneous disease comprising three major subtypes that vary in their histology, clinical course and driver mutations. These subtypes include clear cell RCC, papillary RCC and chromophobe RCC. Molecular analyses of hereditary and…
Source: www.nature.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 38Is Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma a Disease-Modifying Therapy? - 2 month(s) ago
Retrospective and prospective studies have shown that SABR can be safely combined with immunotherapy, delay initiation of systemic therapy, and control progressing lesions without changing systemic therapy in patients with oligometastatic RCC. Larger randomized trials are needed to consolidate the role of SABR in this space.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Chatted w/ @medpagetoday on our @JCOGO_ASCO study on the evolution of systemic #RCC therapy in Canada, highlighting the levers in public health care systems https://t.co/mhEQDRIGf3 Yeoman effort by @luisamcardenas w/ @UroOncMD @DrDanielHeng @nbasappaCCI @SiTanguay & many! 👏 🙏 https://t.co/vcYJtKrKIi https://t.co/3dttBJAVuD